Takeda

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Takeda sits in the top decile of US sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count).

408 total trials 49 currently recruiting 284 completed top decile by trial count

Takeda: 408 sponsored US clinical trials, 49 recruiting.

Takeda sponsors 408 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 284 completed. 174 of these trials are in Phase 3-4 (later-stage) and 209 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Volunteers, with 16 trials.

Top-decile sponsor footprint

Takeda ranks in the top decile of sponsors by registered trial count (#88 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

284 of 340 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

408 total, page 2 of 9

ACTIVE NOT RECRUITING Phase 3

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076

ACTIVE NOT RECRUITING Phase 3

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

NCT05899673

ACTIVE NOT RECRUITING Phase 1

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

NCT05886491

ACTIVE NOT RECRUITING Phase 2

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT05714969

ACTIVE NOT RECRUITING

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

NCT04961840

ACTIVE NOT RECRUITING Phase 2

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT05020015

ACTIVE NOT RECRUITING

A Study of Surgical Interventions in Fistulizing Conditions

NCT04940611

ACTIVE NOT RECRUITING Phase 4

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

NCT04809363

ACTIVE NOT RECRUITING

Post-Marketing Study of Prucalopride Safety In Pregnancy

NCT04869280

ACTIVE NOT RECRUITING Phase 1

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT04420884

ACTIVE NOT RECRUITING Phase 3

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT04129502

ACTIVE NOT RECRUITING Phase 1

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097

ACTIVE NOT RECRUITING Phase 3

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326

ACTIVE NOT RECRUITING Phase 4

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

NCT03173092

ACTIVE NOT RECRUITING Phase 1

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

NCT02979522

ACTIVE NOT RECRUITING Phase 1

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

NCT02716116

ACTIVE NOT RECRUITING

A Registry for Participants With Chronic Hypoparathyroidism

NCT01922440

NOT YET RECRUITING

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT07250815

COMPLETED Phase 1

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

NCT06935266

COMPLETED Phase 1

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967

COMPLETED Phase 1

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943

COMPLETED Phase 1

A First-In-Human Study of TAK-004 in Healthy Adults

NCT06236009

COMPLETED Phase 3

A Study of TAK-861 for the Treatment of Narcolepsy Type 1

NCT06470828

COMPLETED Phase 1

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

NCT06258265

COMPLETED Phase 1

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

NCT06290050

COMPLETED

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

NCT06150534

COMPLETED Phase 1

A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

NCT06132867

COMPLETED Phase 3

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

NCT06108544

COMPLETED Phase 3

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

NCT06088043

COMPLETED Phase 2

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035

COMPLETED Phase 1

A Study of TAK-279 in Adults With or Without Kidney Problems

NCT05992155

COMPLETED Phase 1

A Study of TAK-279 in Adults With or Without Liver Damage

NCT05976321

COMPLETED Phase 1

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

NCT05995249

COMPLETED Phase 1

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822

COMPLETED Phase 1

A Study of TAK-227 in Healthy Adults

NCT05818956

TERMINATED Phase 2

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

NCT05814016

COMPLETED

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

NCT05803200

COMPLETED Phase 1

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

NCT06268301

TERMINATED Phase 1

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682

COMPLETED Phase 2

A Study of TAK-861 in Participants With Narcolepsy Type 1

NCT05687903

COMPLETED Phase 2

A Study of TAK-861 in Participants With Narcolepsy Type 2

NCT05687916

COMPLETED Phase 2

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391

COMPLETED Phase 1

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

NCT05602818

COMPLETED

Virtual Celiac Symptoms Study in Adults and Teenagers

NCT05309330

COMPLETED Phase 1

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

NCT05174221

COMPLETED Phase 2

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

NCT05353985

COMPLETED Phase 2

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123

COMPLETED

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT05363358

COMPLETED Phase 1

Maribavir Food-Effect Study in Healthy Adults Participants

NCT05382104

TERMINATED Phase 1

First-in-Human Study of TAK-280 in Participants With Solid Tumors

NCT05220098

← Previous Page 2 of 9 Next →

What is open in the Takeda pipeline

49 recruiting of 408 indexed (12% open); 284 completed (70%).

Phase mix: 174 late (III/IV) vs 209 early (I/II) (balanced across stages).

Top condition: Healthy Volunteers (16 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Takeda: open-pipeline peers nationwide

Peers matched on 408 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 10%15%20%25% Total trials Recruiting share TakedaUniversity of Kansas Medical CenterCase Comprehensive Cancer CenterUniversity of NebraskaSt. Jude Children's Research HospitalArcus BiosciencesArdelyxKyowa Kirin Co.East Carolina University
Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Takeda sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 408 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this Takeda page

408 registered trials is a research-attention snapshot, not an endorsement of Takeda or any single study.

  • 49 of Takeda's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy Volunteers is the condition Takeda studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Volunteers trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Takeda pipeline card: 408 registered trials from official public datasets.Report a data error.